Pharmacokinetics, dose proportionality and permeability of S002-333 and its enantiomers, a potent antithrombotic agent, in rabbits. (2nd November 2015)

• Record Type: Journal Article
• Authors: Saxena, Amrita; Valicherla, Guru R.; Joshi, Pankaj; Saxena, Rohit; Cheruvu, Srikanth H.; Bhunia, Shome S.; Jain, Girish K.; Siddiqui, Hefazat H.; Saxena, Anil K.; Gayen, Jiaur R.
• Is Part Of: Xenobiotica. Volume 45:Number 11(2015:Nov.)
• Page Start: 1016
• Page End: 1023
• Publication Date: 2015-11-02
• Subjects: Bioavailability -- dose proportionality -- enantiomers -- pharmacokinetics -- permeability; Metabolism -- Periodicals; Drugs -- Physiological effect -- Periodicals; Food additives -- Periodicals; Chemicals -- Physiological effect -- Periodicals; Biochemistry -- Periodicals; Pharmaceutical Preparations -- metabolism -- Periodicals; Metabolism -- Periodicals; 574.133
• DOI: 10.3109/00498254.2015.1034224
• Languages: English
• ISSNs: 0049-8254

Abstract

Abstract: 1. S002-333 [(2-(4′-methoxy-benzenesulfonyl)-2, 3, 4, 9-tetrahydro-1H-pyrido (3, 4-b) indole-3-carboxylic acid amide)] is a novel and potent antithrombotic active agent. The present work investigates the pharmacokinetics, bioavailability, dose proportionality and permeability of the racemate, S002-333 in male New Zealand White (NZW) rabbits. 2. Rabbits were administered single intravenous (i.v.) (2 mg/kg) and three oral doses of 10, 20 and 40 mg/kg of S002-333, respectively, at different occasions to evaluate dose proportionality. Serial blood samples were collected and analyzed by a liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Since S002-333 is a racemate consisting of S004-1032 ( R ) and S007-1558 ( S ), same samples were analyzed using a chiralcel column so as to evaluate the respective enantiomers. 3. The peak plasma concentration, after oral administration, occurred at ∼10 h post-dose. The clearance (CL) and volume of distribution ( V d ) after i.v. dose were found to be 3.05 ± 0.09 l/h/kg and 6.73 ± 1.16 l/kg, respectively. The absolute oral bioavailability of S002-333 was 16.32%, whereas it was 6.62 and 5.90% for R- and S- enantiomers, respectively. The absolute bioavailability of 10, 20 and 40 mg/kg doses were found to be 27.91, 14.39 and 16.91%, respectively. The PAMPA (parallel artificial membrane permeability assay) assay shows that S002-333 has a low-passive permeability at gastric and intestinal environment. 4. In conclusion, S002-333 has low-passive permeability, low CL and large V d . The R- enantiomer has a "slightly" greater bioavailability than the S- enantiomer.